ANIK Q1 2019 Earnings — Anika Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ANIKAnika Therapeutics, Inc.

$208M

Q1 2019 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$25M+16.3% YoY

Gross Profit

$17M70.4% margin

Operating Income

$5M22.2% margin

Net Income

$5M18.2% margin

EPS (Diluted)

$0.31

QoQ Revenue Growth

-8.3%

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

$7M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$307M

Total Liabilities

$38M

Stockholders' Equity

$269M

Cash & Equivalents

$96M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$25M	$21M	+16.3%
Gross Profit	$17M	$13M	+29.8%
Operating Income	$5M	-$8M	+170.0%
Net Income	$5M	-$7M	+167.4%

Revenue Segments

Product

$25M50%

Orthobiologics

$22M44%

Manufactured Product, Other

$1M3%

Surgical

$1M3%

Dermal

$129,0000%

Geographic Segments

UNITED STATES

$20M89%

Europe

$3M11%